Treatment response assessment in mCRPC: is PSMA-PET/CT going to take the lead?
The assessment of response to therapy in prostate cancer (PCa) patients is an ongoing, open issue. Prostate-specific antigen has limitations, especially in advanced metastatic PCa, which often displays intratumor variability in terms of response to therapy. Conventional imaging (i.e. computerized to...
Sparad:
| Huvudupphov: | , , , |
|---|---|
| Materialtyp: | Artigo |
| Språk: | Inglês |
| Utgiven: |
SAGE Publishing
2024-10-01
|
| Serie: | Therapeutic Advances in Medical Oncology |
| Länkar: | https://doi.org/10.1177/17588359241258367 |
| Taggar: |
Inga taggar, Lägg till första taggen!
|